3 OPI de biotecnología, $703 millones recaudados para ensayos clínicos en cáncer, inmunología y trastornos endocrinos.
Head and neck cancers can be treated with various drugs, but some patients require better therapeutic options. Bicara Therapeutics has raised $315 million through an IPO to fund a pivotal study for a new therapy aimed at improving outcomes for patients with head and neck squamous cell carcinoma (HNSCC). Bicara exceeded its fundraising goals, offering … Leer más
